December 10, 2020

Hello TriHealth family,

Over the past two weeks, TriHealth has begun utilizing an investigational monoclonal antibody therapy, bamlanivimab, for limited use with certain COVID-19 patients. Not to be confused with the COVID-19 vaccine, this infusion treatment is intended for patients with mild-to-moderate COVID-19 symptoms who are at high-risk of developing severe symptoms, as it has shown efficacy in reducing COVID-19-related hospitalizations. Bamlanivimab is not a treatment to be used on patients already hospitalized. I am joined in this week’s video by Dr. Steve Blatt, medical director of Infectious Diseases; Matthew Bremer, clinical manager for Pharmacy; and Chrissy Bean, Infusion Center administrator, for more information on how monoclonal antibody therapy can serve as a new targeted weapon in our larger fight against COVID-19. 

Click here to view this week’s video in a separate window. 
Please note: closed captioning can be turned off by clicking the “CC” button in the lower right corner of your video player.

We are continually updating our COVID policies and guidelines throughout this surge. I encourage you to frequently check our COVID hub on Bridge for the latest policy, guideline and statistical updates on COVID-19. 

Thank you for all you do every day to safely care for and support our TriHealth patients and the community.